Spatium Medical introduces the world’s first medical insufflator that ensures stable workspace at lowest insufflation and ventilation pressure with three patented technologies addressing three unmet needs.

StemX Bio's revolutionary human in vitro 3D pancreatic model will completely transform the area of diabetes drug discovery. This innovative approach directly addresses the critical unmet need within the diabetes research community for more accurate and physiologically relevant in vitro models.

To become the new standard in vascular treatment. By bringing regenerative capacity for the first time to a stent, a wide range of clinical applications will benefit from our innovative approach.

Streasure4Health is developing the first objective test for chronic fatigue and post-exertional malaise (PEM)—a core exhausting and disabling symptom in disorders such as Long COVID, burnout, and PTSD, affecting over 250 million people worldwide.

SupraVision is developing an innovative cell therapy for age-related macular degeneration (AMD) to restore lost vision by replacing damaged retinal tissue.

T Cell Factory (TCF) will identify and develop therapeutic T cell receptor (TCR) genes for the growing market of cancer therapies.

We at TargED have developed MICROLYSE, an innovative fusion-protein that has an antibody domain that recognizes microthrombi and an enzymatic domain that breaks them down.

THRONCAT Analytics offers a service in optimizing mRNA sequences for safety by detecting, identifying, and quantifying protein by-products of mRNA therapeutics.

At Toxys we strongly believe in bringing high quality information to our partners and clients. I strongly believe that the future for human safety assessment is not with simple tests that only provide a yes or no answers, but advanced in vitro models that provide reliable and relevant insight into the mechanism of action of novel chemicals and materials. We are committed to support our partners in understanding their latest compounds and in making the right decisions during R&D of novel products

At TrianecT, we develop StrokePointer: a fast pre-hospital solution for early stroke diagnosis.